SARMs Dry Mass & Myostatin Stack: YK-11 + Andarine (S4) + TUDCA + Enclomiphene PCT (Driada Medical)

Advanced Myostatin Inhibition & Vascular Definition Stack

Engineered for elite athletes targeting dense muscle accretion devoid of fluid retention, this advanced protocol combines the potent gene-transcription capabilities of Myostan (YK-11) with the selective androgenic affinity of Andarine (S4). YK-11 operates as a steroidal myostatin inhibitor and partial agonist of the androgen receptor, inducing follistatin expression to bypass intrinsic physiological limits on hypertrophy. Simultaneously, Andarine drives cross-sectional muscle density, vascularity, and lipolysis without aromatising into estrogen. Athletes exploring targeted SARMs protocols utilize this synergy to elicit pronounced morphological hardening, accelerated myofibrillar protein synthesis, and enhanced muscular power output across a targeted seven-week performance phase.

Because both agents exhibit high binding affinity, managing systemic balance and internal organ stress is critical. Unlike harsh non-selective oral agents found in conventional Oral-Only Steroid Cycles, this stack integrates 500 mg of Allaes TUDCA daily to safeguard biliary flow and alleviate hepatic strain. The cycle finishes with pharmaceutical-grade Enclomilad (Enclomiphene citrate) from Driada Medical, ensuring an immediate endocrine reboot upon completion. This targeted approach prevents negative feedback on the hypothalamic-pituitary-testicular axis (HPTA), preserving lean gains and restoring endogenous gonadotropin release efficiently.

Complete Kit Package Components

• 1 × Myostan 5 mg (YK-11) | 5mg/tab/50tabs
• 2 × Andarine 25 mg (S4) | 25mg/tab/50tabs
• 1 × Allaes TUDCA 500 mg | 500mg / 60 capsules
• 1 × Enclomilad 12.5 mg (Enclomiphene citrate) - Driada | 50tabs | 12,5 mg/tab

Weekly Protocol & Dosage Administration Schedule

Clinical Protocol, Half-Life Management & Post-Cycle Therapy

During Weeks 1 through 7, split administration is required to stabilize circulating plasma concentrations. YK-11 possesses a short biological half-life of roughly 6 to 10 hours; take 5 mg (1 tablet) in the morning and 5 mg in the evening. Andarine (S4) carries an approximate 4-to-6-hour half-life, making a split dose of 25 mg in the morning and 25 mg pre-workout or late afternoon optimal to mitigate ocular receptor saturation. Administer 500 mg of Allaes TUDCA once daily alongside your fattiest meal to maintain biliary homeostasis. As with advanced Steroid Cycles, maintaining consistent dosing intervals ensures sustained anabolic signaling while reducing potential receptor-level desensitization.

Immediately upon finishing Week 7, transition into the critical endocrine recovery phase (Weeks 8–11). Unlike non-selective SERMs such as standard Clomid, Enclomilad consists purely of the trans-isomer of clomiphene, directly antagonizing hypothalamic estrogen receptors without estrogenic side effects. Administer 12.5 mg to 25 mg of Enclomilad every morning for 4 consecutive weeks. This elevates LH and FSH secretion rapidly, restarting endogenous intratesticular testosterone synthesis, maintaining your newly built dry contractile tissue, and normalizing systemic lipid profiles post-cycle.

Synergistic Performance & Physique Benefits

• Myostatin Inhibition via Follistatin Upregulation: YK-11 actively suppresses myostatin expression, shattering natural genetic ceilings to accelerate dry myofibrillar hypertrophy and rapid strength gains.
• Hardened Vascular Conditioning: Andarine (S4) enhances intracellular glycogen retention and drives intramuscular fat oxidation, producing an ultra-dry, vascular look free from subcutaneous water retention.
• Comprehensive Hepatic & Cellular Shielding: High-grade Allaes TUDCA (500 mg/day) maintains healthy hepatic enzyme profiles, promotes smooth bile acid circulation, and prevents liver cholestasis during the active SARM phase.
• Rapid Endocrine Restoration: Enclomilad provides pure enclomiphene antagonistic action on estrogen receptors, elevating LH and FSH for reliable HPTA recovery and permanent retention of acquired muscle mass.